Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-11-18

AUTHORS

Jianda Yuan, Geoffrey Y Ku, Matthew Adamow, Zhenyu Mu, Sapna Tandon, Drew Hannaman, Paul Chapman, Gary Schwartz, Richard Carvajal, Katherine S Panageas, Alan N Houghton, Jedd D Wolchok

ABSTRACT

BackgroundPrior studies show that intramuscular injection and particle-mediated epidermal delivery of xenogeneic melanosomal antigens (tyrosinase or Tyr, gp100) induce CD8+ T cell responses to the syngeneic protein. To further define the optimal vaccination strategy, we conducted a phase I study of in vivo electroporation (EP) of a murine Tyr DNA vaccine (pINGmuTyr) in malignant melanoma patients.MethodsHuman leukocyte antigen (HLA)-A1, A2, A24 or B35 stage IIb-IV melanoma patients received up to five doses of the mouse tyrosinase DNA vaccine by EP every three weeks at dose levels of 0.2 mg, 0.5 mg, or 1.5 mg per injection. Peripheral blood mononuclear cells (PBMC) were collected, cultured with a peptide pool containing eight HLA class I-restricted Tyr-specific T-cell epitopes, and analyzed by HLA-A*0101-restricted tetramers and intracellular cytokine staining (ICS).ResultsTwenty-four patients received ≥1 dose of the pINGmuTyr vaccine; PBMCs from 21 patients who completed all five doses were available for Tyr immune assays. The only common toxicity was grade 1 injection site reaction. Six of 15 patients (40%) in the 1.5 mg dose cohort developed Tyr-reactive CD8+ T cell responses following stimulation, defined as a ≥3 standard deviation increase in baseline reactivity by tetramer or ICS assays. No Tyr-reactive CD8+ T cell response was detected in the 0.2 mg and 0.5 mg dose cohort patients. Epitope spreading of CD8+ T cell response to NY-ESO-1 was observed in one patient with vitiligo. One patient subsequently received ipilimumab and developed an enhanced Tyr-reactive response with polyfunctional cytokine profile. After a median follow-up of 40.9 months, median survival has not been reached.ConclusionsA regimen of five immunizations with pINGmuTyr administered by EP was found to be safe and resulted in Tyr-reactive immune responses in six of 15 patients at 1.5 mg dose cohort.Trial registrationClinicalTrials.gov NCT00471133 More... »

PAGES

20

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/2051-1426-1-20

DOI

http://dx.doi.org/10.1186/2051-1426-1-20

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035943441

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24829756


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuan", 
        "givenName": "Jianda", 
        "id": "sg:person.012510205147.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012510205147.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ku", 
        "givenName": "Geoffrey Y", 
        "id": "sg:person.01136712123.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136712123.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adamow", 
        "givenName": "Matthew", 
        "id": "sg:person.014666710657.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014666710657.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mu", 
        "givenName": "Zhenyu", 
        "id": "sg:person.01230352143.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230352143.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tandon", 
        "givenName": "Sapna", 
        "id": "sg:person.0577557275.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577557275.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ichor Medical System, Inc., 92121, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ichor Medical System, Inc., 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hannaman", 
        "givenName": "Drew", 
        "id": "sg:person.01234252565.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234252565.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chapman", 
        "givenName": "Paul", 
        "id": "sg:person.01155324177.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155324177.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "Gary", 
        "id": "sg:person.012707142152.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012707142152.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, NY10065, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, NY10065, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Panageas", 
        "givenName": "Katherine S", 
        "id": "sg:person.01356724235.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356724235.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA", 
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Houghton", 
        "givenName": "Alan N", 
        "id": "sg:person.0740431650.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740431650.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA", 
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolchok", 
        "givenName": "Jedd D", 
        "id": "sg:person.0645565266.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645565266.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00262-011-1011-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043032376", 
          "https://doi.org/10.1007/s00262-011-1011-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00268-010-0859-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050504693", 
          "https://doi.org/10.1007/s00268-010-0859-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nri2506", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006865477", 
          "https://doi.org/10.1038/nri2506"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-11-18", 
    "datePublishedReg": "2013-11-18", 
    "description": "BackgroundPrior studies show that intramuscular injection and particle-mediated epidermal delivery of xenogeneic melanosomal antigens (tyrosinase or Tyr, gp100) induce CD8+ T cell responses to the syngeneic protein. To further define the optimal vaccination strategy, we conducted a phase I study of in vivo electroporation (EP) of a murine Tyr DNA vaccine (pINGmuTyr) in malignant melanoma patients.MethodsHuman leukocyte antigen (HLA)-A1, A2, A24 or B35 stage IIb-IV melanoma patients received up to five doses of the mouse tyrosinase DNA vaccine by EP every three weeks at dose levels of 0.2\u00a0mg, 0.5\u00a0mg, or 1.5\u00a0mg per injection. Peripheral blood mononuclear cells (PBMC) were collected, cultured with a peptide pool containing eight HLA class I-restricted Tyr-specific T-cell epitopes, and analyzed by HLA-A*0101-restricted tetramers and intracellular cytokine staining (ICS).ResultsTwenty-four patients received \u22651 dose of the pINGmuTyr vaccine; PBMCs from 21 patients who completed all five doses were available for Tyr immune assays. The only common toxicity was grade 1 injection site reaction. Six of 15 patients (40%) in the 1.5\u00a0mg dose cohort developed Tyr-reactive CD8+ T cell responses following stimulation, defined as a \u22653 standard deviation increase in baseline reactivity by tetramer or ICS assays. No Tyr-reactive CD8+ T cell response was detected in the 0.2\u00a0mg and 0.5\u00a0mg dose cohort patients. Epitope spreading of CD8+ T cell response to NY-ESO-1 was observed in one patient with vitiligo. One patient subsequently received ipilimumab and developed an enhanced Tyr-reactive response with polyfunctional cytokine profile. After a median follow-up of 40.9\u00a0months, median survival has not been reached.ConclusionsA regimen of five immunizations with pINGmuTyr administered by EP was found to be safe and resulted in Tyr-reactive immune responses in six of 15 patients at 1.5\u00a0mg dose cohort.Trial registrationClinicalTrials.gov NCT00471133", 
    "genre": "article", 
    "id": "sg:pub.10.1186/2051-1426-1-20", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2435475", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "publisher": "BMJ", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "1"
      }
    ], 
    "keywords": [
      "peripheral blood mononuclear cells", 
      "T cell responses", 
      "intracellular cytokine staining", 
      "DNA vaccine", 
      "cell responses", 
      "dose cohorts", 
      "melanoma patients", 
      "grade 1 injection site reactions", 
      "particle-mediated epidermal delivery", 
      "ResultsTwenty-four patients", 
      "polyfunctional cytokine profile", 
      "injection site reactions", 
      "malignant melanoma patients", 
      "NY-ESO-1", 
      "blood mononuclear cells", 
      "HLA class I", 
      "T cell epitopes", 
      "optimal vaccination strategy", 
      "common toxicities", 
      "cohort patients", 
      "cytokine staining", 
      "cytokine profile", 
      "median survival", 
      "melanosomal antigens", 
      "immunologic response", 
      "leukocyte antigen", 
      "mononuclear cells", 
      "site reactions", 
      "ICS assays", 
      "vaccination strategies", 
      "baseline reactivity", 
      "intramuscular injection", 
      "malignant melanoma", 
      "BackgroundPrior studies", 
      "immune response", 
      "patients", 
      "CD8", 
      "immune assays", 
      "dose levels", 
      "peptide pools", 
      "epidermal delivery", 
      "vaccine", 
      "phase I", 
      "class I", 
      "standard deviation increase", 
      "vivo electroporation", 
      "cohort", 
      "antigen", 
      "doses", 
      "epitopes", 
      "injection", 
      "response", 
      "deviation increase", 
      "assays", 
      "ipilimumab", 
      "regimen", 
      "immunization", 
      "HLA", 
      "electroporation", 
      "vitiligo", 
      "melanoma", 
      "dose", 
      "weeks", 
      "months", 
      "stimulation", 
      "survival", 
      "staining", 
      "A24", 
      "toxicity", 
      "delivery", 
      "cells", 
      "A2", 
      "A1", 
      "levels", 
      "protein", 
      "study", 
      "increase", 
      "profile", 
      "reactivity", 
      "strategies", 
      "pool", 
      "tetramer", 
      "reaction"
    ], 
    "name": "Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma", 
    "pagination": "20", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035943441"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/2051-1426-1-20"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24829756"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/2051-1426-1-20", 
      "https://app.dimensions.ai/details/publication/pub.1035943441"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_590.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/2051-1426-1-20"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/2051-1426-1-20'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/2051-1426-1-20'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/2051-1426-1-20'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/2051-1426-1-20'


 

This table displays all metadata directly associated to this object as RDF triples.

243 TRIPLES      21 PREDICATES      111 URIs      100 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/2051-1426-1-20 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author N068e6c951a124ebfbabd21f1f0cec5ca
4 schema:citation sg:pub.10.1007/s00262-011-1011-9
5 sg:pub.10.1007/s00268-010-0859-8
6 sg:pub.10.1038/nri2506
7 schema:datePublished 2013-11-18
8 schema:datePublishedReg 2013-11-18
9 schema:description BackgroundPrior studies show that intramuscular injection and particle-mediated epidermal delivery of xenogeneic melanosomal antigens (tyrosinase or Tyr, gp100) induce CD8+ T cell responses to the syngeneic protein. To further define the optimal vaccination strategy, we conducted a phase I study of in vivo electroporation (EP) of a murine Tyr DNA vaccine (pINGmuTyr) in malignant melanoma patients.MethodsHuman leukocyte antigen (HLA)-A1, A2, A24 or B35 stage IIb-IV melanoma patients received up to five doses of the mouse tyrosinase DNA vaccine by EP every three weeks at dose levels of 0.2 mg, 0.5 mg, or 1.5 mg per injection. Peripheral blood mononuclear cells (PBMC) were collected, cultured with a peptide pool containing eight HLA class I-restricted Tyr-specific T-cell epitopes, and analyzed by HLA-A*0101-restricted tetramers and intracellular cytokine staining (ICS).ResultsTwenty-four patients received ≥1 dose of the pINGmuTyr vaccine; PBMCs from 21 patients who completed all five doses were available for Tyr immune assays. The only common toxicity was grade 1 injection site reaction. Six of 15 patients (40%) in the 1.5 mg dose cohort developed Tyr-reactive CD8+ T cell responses following stimulation, defined as a ≥3 standard deviation increase in baseline reactivity by tetramer or ICS assays. No Tyr-reactive CD8+ T cell response was detected in the 0.2 mg and 0.5 mg dose cohort patients. Epitope spreading of CD8+ T cell response to NY-ESO-1 was observed in one patient with vitiligo. One patient subsequently received ipilimumab and developed an enhanced Tyr-reactive response with polyfunctional cytokine profile. After a median follow-up of 40.9 months, median survival has not been reached.ConclusionsA regimen of five immunizations with pINGmuTyr administered by EP was found to be safe and resulted in Tyr-reactive immune responses in six of 15 patients at 1.5 mg dose cohort.Trial registrationClinicalTrials.gov NCT00471133
10 schema:genre article
11 schema:isAccessibleForFree true
12 schema:isPartOf N3783f47a78314ca7a2f63e5a39959f21
13 Nfe374f73216d4cfb9eac598b5dd9d607
14 sg:journal.1049249
15 schema:keywords A1
16 A2
17 A24
18 BackgroundPrior studies
19 CD8
20 DNA vaccine
21 HLA
22 HLA class I
23 ICS assays
24 NY-ESO-1
25 ResultsTwenty-four patients
26 T cell epitopes
27 T cell responses
28 antigen
29 assays
30 baseline reactivity
31 blood mononuclear cells
32 cell responses
33 cells
34 class I
35 cohort
36 cohort patients
37 common toxicities
38 cytokine profile
39 cytokine staining
40 delivery
41 deviation increase
42 dose
43 dose cohorts
44 dose levels
45 doses
46 electroporation
47 epidermal delivery
48 epitopes
49 grade 1 injection site reactions
50 immune assays
51 immune response
52 immunization
53 immunologic response
54 increase
55 injection
56 injection site reactions
57 intracellular cytokine staining
58 intramuscular injection
59 ipilimumab
60 leukocyte antigen
61 levels
62 malignant melanoma
63 malignant melanoma patients
64 median survival
65 melanoma
66 melanoma patients
67 melanosomal antigens
68 mononuclear cells
69 months
70 optimal vaccination strategy
71 particle-mediated epidermal delivery
72 patients
73 peptide pools
74 peripheral blood mononuclear cells
75 phase I
76 polyfunctional cytokine profile
77 pool
78 profile
79 protein
80 reaction
81 reactivity
82 regimen
83 response
84 site reactions
85 staining
86 standard deviation increase
87 stimulation
88 strategies
89 study
90 survival
91 tetramer
92 toxicity
93 vaccination strategies
94 vaccine
95 vitiligo
96 vivo electroporation
97 weeks
98 schema:name Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma
99 schema:pagination 20
100 schema:productId N0354620d897d4cb19807c216171dabdc
101 N683a3401b4784fa493ceeb5414c8255f
102 N8ad39af125bc44b8b9ddeb8c49bb26bb
103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035943441
104 https://doi.org/10.1186/2051-1426-1-20
105 schema:sdDatePublished 2022-11-24T20:56
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher Nff2b889584b849d1881f7621207dbe17
108 schema:url https://doi.org/10.1186/2051-1426-1-20
109 sgo:license sg:explorer/license/
110 sgo:sdDataset articles
111 rdf:type schema:ScholarlyArticle
112 N03504a8c054f4c76af6d5362e0ab47d8 rdf:first sg:person.012707142152.08
113 rdf:rest Nceeadab1291d45e9ab46243e629f7ede
114 N0354620d897d4cb19807c216171dabdc schema:name dimensions_id
115 schema:value pub.1035943441
116 rdf:type schema:PropertyValue
117 N068e6c951a124ebfbabd21f1f0cec5ca rdf:first sg:person.012510205147.27
118 rdf:rest Neffcfc99f14b42acaa43c14535371156
119 N263bd2a2580d4b71b0af0365004a490d rdf:first sg:person.0577557275.28
120 rdf:rest Nb8cc17a9f602481798e2fa6200cc9df5
121 N3783f47a78314ca7a2f63e5a39959f21 schema:issueNumber 1
122 rdf:type schema:PublicationIssue
123 N683a3401b4784fa493ceeb5414c8255f schema:name pubmed_id
124 schema:value 24829756
125 rdf:type schema:PropertyValue
126 N8ad39af125bc44b8b9ddeb8c49bb26bb schema:name doi
127 schema:value 10.1186/2051-1426-1-20
128 rdf:type schema:PropertyValue
129 N92c23228d25241c6b28a0a57a8b2a0a8 rdf:first sg:person.0740431650.46
130 rdf:rest N9712d7151f57465fa7babc04a3ef3821
131 N9712d7151f57465fa7babc04a3ef3821 rdf:first sg:person.0645565266.33
132 rdf:rest rdf:nil
133 N9a87b9458b95442983983933c5a2f41c rdf:first sg:person.01356724235.54
134 rdf:rest N92c23228d25241c6b28a0a57a8b2a0a8
135 Nb8cc17a9f602481798e2fa6200cc9df5 rdf:first sg:person.01234252565.18
136 rdf:rest Nd4dba6c4193a411a98fa2a002d6c687d
137 Nceeadab1291d45e9ab46243e629f7ede rdf:first sg:person.0726366600.25
138 rdf:rest N9a87b9458b95442983983933c5a2f41c
139 Nd4dba6c4193a411a98fa2a002d6c687d rdf:first sg:person.01155324177.77
140 rdf:rest N03504a8c054f4c76af6d5362e0ab47d8
141 Neffcfc99f14b42acaa43c14535371156 rdf:first sg:person.01136712123.05
142 rdf:rest Nff9aefca12724f7f9d84e679daebe0d1
143 Nfe374f73216d4cfb9eac598b5dd9d607 schema:volumeNumber 1
144 rdf:type schema:PublicationVolume
145 Nff2b889584b849d1881f7621207dbe17 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 Nff393bce47d74069b6ceb0591d7176b3 rdf:first sg:person.01230352143.27
148 rdf:rest N263bd2a2580d4b71b0af0365004a490d
149 Nff9aefca12724f7f9d84e679daebe0d1 rdf:first sg:person.014666710657.34
150 rdf:rest Nff393bce47d74069b6ceb0591d7176b3
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
155 schema:name Immunology
156 rdf:type schema:DefinedTerm
157 sg:grant.2435475 http://pending.schema.org/fundedItem sg:pub.10.1186/2051-1426-1-20
158 rdf:type schema:MonetaryGrant
159 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1186/2051-1426-1-20
160 rdf:type schema:MonetaryGrant
161 sg:journal.1049249 schema:issn 2051-1426
162 schema:name Journal for ImmunoTherapy of Cancer
163 schema:publisher BMJ
164 rdf:type schema:Periodical
165 sg:person.01136712123.05 schema:affiliation grid-institutes:grid.51462.34
166 schema:familyName Ku
167 schema:givenName Geoffrey Y
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136712123.05
169 rdf:type schema:Person
170 sg:person.01155324177.77 schema:affiliation grid-institutes:grid.51462.34
171 schema:familyName Chapman
172 schema:givenName Paul
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155324177.77
174 rdf:type schema:Person
175 sg:person.01230352143.27 schema:affiliation grid-institutes:grid.51462.34
176 schema:familyName Mu
177 schema:givenName Zhenyu
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230352143.27
179 rdf:type schema:Person
180 sg:person.01234252565.18 schema:affiliation grid-institutes:None
181 schema:familyName Hannaman
182 schema:givenName Drew
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234252565.18
184 rdf:type schema:Person
185 sg:person.012510205147.27 schema:affiliation grid-institutes:grid.51462.34
186 schema:familyName Yuan
187 schema:givenName Jianda
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012510205147.27
189 rdf:type schema:Person
190 sg:person.012707142152.08 schema:affiliation grid-institutes:grid.51462.34
191 schema:familyName Schwartz
192 schema:givenName Gary
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012707142152.08
194 rdf:type schema:Person
195 sg:person.01356724235.54 schema:affiliation grid-institutes:grid.51462.34
196 schema:familyName Panageas
197 schema:givenName Katherine S
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356724235.54
199 rdf:type schema:Person
200 sg:person.014666710657.34 schema:affiliation grid-institutes:grid.51462.34
201 schema:familyName Adamow
202 schema:givenName Matthew
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014666710657.34
204 rdf:type schema:Person
205 sg:person.0577557275.28 schema:affiliation grid-institutes:grid.51462.34
206 schema:familyName Tandon
207 schema:givenName Sapna
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577557275.28
209 rdf:type schema:Person
210 sg:person.0645565266.33 schema:affiliation grid-institutes:grid.51462.34
211 schema:familyName Wolchok
212 schema:givenName Jedd D
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645565266.33
214 rdf:type schema:Person
215 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.51462.34
216 schema:familyName Carvajal
217 schema:givenName Richard
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
219 rdf:type schema:Person
220 sg:person.0740431650.46 schema:affiliation grid-institutes:grid.51462.34
221 schema:familyName Houghton
222 schema:givenName Alan N
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740431650.46
224 rdf:type schema:Person
225 sg:pub.10.1007/s00262-011-1011-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043032376
226 https://doi.org/10.1007/s00262-011-1011-9
227 rdf:type schema:CreativeWork
228 sg:pub.10.1007/s00268-010-0859-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050504693
229 https://doi.org/10.1007/s00268-010-0859-8
230 rdf:type schema:CreativeWork
231 sg:pub.10.1038/nri2506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006865477
232 https://doi.org/10.1038/nri2506
233 rdf:type schema:CreativeWork
234 grid-institutes:None schema:alternateName Ichor Medical System, Inc., 92121, San Diego, CA, USA
235 schema:name Ichor Medical System, Inc., 92121, San Diego, CA, USA
236 rdf:type schema:Organization
237 grid-institutes:grid.51462.34 schema:alternateName Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, NY10065, New York, USA
238 Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA
239 Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA
240 schema:name Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, NY10065, New York, USA
241 Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA
242 Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, NY10065, New York, USA
243 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...